November 2023 | Hergenrother Lab

Team discovers rules for breaking into Pseudomonas

Researchers report in the journal Nature that they have found a way to get antibacterial drugs through the nearly impenetrable outer membrane of Pseudomonas aeruginosa, a bacterium that – once it infects a person – is notoriously difficult to treat. Read more

Co-authors Dr. Myung Ryul Lee, left, Professor Paul Hergenrother, center, and Hergenrother Lab grad student Morgan Gugger, have worked to find solutions for delivering antibiotics to battle P. aeruginosa infections, which currently is resistant to most methods. Their work found new pathways that offer new pathways for future antibiotic development. Photo taken at the University of Illinois Urbana-Champaign on Wednesday, June 17, 2023. (Photo by Fred Zwicky / University of Illinois Urbana-Champaign)

Prof. David Shapiro and Prof. Paul Hergenrother

Unprecedented Compound Takes a Step Toward Breast Cancer Clinical Trials

Estrogen receptor-positive breast cancer is the most common form of breast cancer, affecting approximately 75% of breast cancer patients. In advanced and metastatic form, it is lethal, claiming the lives of nearly 350,000 individuals annually. Presently, no drug is able to eradicate these advanced tumors.

Cancer Center at Illinois (CCIL) researchers Paul Hergenrother and David Shapiro are working to change that with the anticancer compound developed in their collaborative labs and now licensed for pre-clinical development.

Month: November 2023

NEW: Rules for compound accumulation in P. aeruginosa published in Nature.

NEW: A compound from the Hergenrother/Shapiro collaboration has been licensed and is advancing toward treatment of breast cancer.